Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Merck's Phase 3 KEYNOTE-B21 Trial Of Keytruda In Combination With Chemotherapy As Adjuvant Treatment, With Or Without Radiotherapy, Did Not Meet Its Primary Endpoint Of Disease-free Survival For Newly Diagnosed, High-risk Endometrial Cancer After Surgery

Author: Benzinga Newsdesk | May 09, 2024 07:30am

Posted In: MRK